Under pressure, Peter Hecht splits Ironwood into two biotechs, spinning out an R&D operation
Ironwood $IRWD is splitting up its business into two distinct halves, spinning out a pipeline of early- and mid-stage drugs into a separate, publicly traded …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
